Observe Medical ASA (OBSRV) Earnings Call Transcript & Summary
February 25, 2020
Earnings Call Speaker Segments
Bjorn Larsson
executiveGood morning, everyone here in the room at Aker Brygge in Oslo, Norway, and to those of you joining us through the webcast. A warm welcome to Observe Medical's quarter 4, 2019 presentation. My name is Bjorn Larsson, and I serve as CEO of Observe Medical. Joining me this morning is Per Arne Nygard, our CFO. During today's presentation, we'll go through the following. We'll provide a brief highlight of Q4. We'll introduce Observe Medical to you in a bit more depth. After that, we'll cover the commercial update on Sippi, our first key product. I'll then pass things over to Per Arne, who will give us a financial update. Then we'll return for a wrap-up and open up for questions from both the room and the web. So when that time comes, please just raise your hand, and I believe there are some instructions on the web. Okay. We will hold this presentation in English, but we'll be glad to take questions in the Q&A in whichever language you prefer. Okay. With that, let's begin. Observe Medical, the highlights of Q4. We successfully completed the de-merger and listing of the company.
Bjorn Larsson
executiveWe spun off the business on 31st of October 2019, and it was listed on the Access Stock Exchange on 4th of November. And in that period, we've brought new leadership on board, and we've managed to firmly set up the company as a standalone entity. We have an organization and a team that is genuinely commercial in focus — not just the organization, but the spirit too. In the third quarter, we carried out the strategy — those of you tuning in in November will recall — and we've kept a clear focus on sales of Sippi. And that has gone great. The response has been great, particularly on the second generation, which was the newly launched version of Sippi. We're in the launch phase — what I tend to call the peri-launch phase. And in that time, of course, revenues are somewhat limited, but we've seen no indication whatsoever of any waning interest. Quite the opposite — it's simply that implementation can sometimes take longer, and sometimes it takes less time. So on behalf of the team at Observe Medical, Per Arne and myself, we're very proud to be on this journey, and now we'll take you into some of the more specific points.
Bjorn Larsson
executiveObserve Medical is a worldwide medtech business that's been set up to expand. So when we say growth, what exactly do we mean? We're talking about expansion, commercial expansion, and that can come about organically. Take our first product, Sippi, as an example. At the moment, we're out there with customers, though it can equally come through, say, growth via mergers and acquisitions. And that's a definite aim here at Observe Medical. First off, commercialize Sippi as our initial product. In parallel, stay opportunistic in seeking solid M&A chances to build up a portfolio for expansion. Sippi, our first product, was developed by the Observe team well before I joined. And it's a system for measuring urine, entirely unique. We'll get into that. And it has excellent trademark and patent protection. And it's available on the market -- in the market, and it has a solid supply and manufacturing organization behind it. It's a sturdy setup for launch. And Sippi's second generation came out in the second half, crucially, in response to what a customer needed, in response to the need for further linking the product to what's known as the patient data management system, which appears more and more often in hospitals. Alright. That's Observe Medical. We're discussing the leadership.
Bjorn Larsson
executiveAll right, so Per Arne is here with me today. Just a few remarks about Per Arne. He's a finance professional with plenty of experience — a CFO and a controller across a range of businesses. Over the past 12 years, Per Arne has worked in the listed arena at multiple companies, multi-consulting among them. He's a highly seasoned financial CFO who has a very solid grip on operations, and that's excellent to have on board. As for me, I come from Sweden. No — but I've got roughly 30 years of experience in life science, medtech, biotech, and pharma, in roles spanning sales, marketing, product, and general management. I also hold the position of Chairman of the Board at a listed company in Sweden. And I'd say I'm certainly confident when it comes to life science and bringing products to market, yet at the same time I stay humble, since every one of these products comes with its own dynamics. But the most important thing is that we have a fantastic cross-functional team. Here at Observe Medical, our headquarters are in Oslo. Operations are mainly based in Gothenburg, where our cross-functional team sits. It's a great location, with a solid medtech cluster surrounding us — which is great for an entrepreneurial company in growth.
Bjorn Larsson
executiveYeah, bringing products to market in medtech — a few words on that. Business is business, but life science and medtech come with their own opportunities and challenges. First of all, in our business, you have to understand the customers, and that's why we have such a sales focus right now — to understand the customers. Then you need a product that performs against that, and in medtech especially, you need to document that very well. The next step is to get what we call regulatory approval. That is the ticket — license to be on the market. In Europe, for example, this is called Medical Device Directory. But that's not enough. That just puts your product on the market. What you need is a value proposition that makes the customer really want to buy your products and solve a problem, and there you need so-called health economics and value evidence. So that is very important. And then you need partners. In some markets, you sell yourself, and in some markets, you use distributors and other partners. And that depends on the geography and the practices in those different regions where you operate. So you need a clear vision, and then you need to be agile and operate depending on the customer segment and the environment where you are, locally.
Bjorn Larsson
executiveSo it's fair to say we're confident, I have confidence in the team, and I feel both confident and humble about this very exciting journey, which is meaningful as well. Let me share a bit about that. In ICUs — and what is an ICU? We're going to discuss the commercialization of Sippi now. An ICU is an intensive care unit. You hear plenty about issues in the health care system, but I can tell you that an ICU works. It's a mission-critical environment where we care for people with severe problems. Inside an ICU, the patient gets monitored day and night, and it's all automated — oxygen levels, the heart, you name it — except for one thing, and that's urine. Measuring urine matters greatly for renal function, a vital sign for the patient, yet it's done manually because automating it is difficult. That can create various challenges. A few of these challenges are as follows: data accuracy. At present, in the ICU, the staff measures manually, and it's subject to subjectivity — not just regarding the volume measured, but also regarding when you measure it. Measurement should happen every hour.
Bjorn Larsson
executiveThat can lead to mistakes made by people and poor choices. Second, time. Doing this by hand consumes time. Quite a lot of time, in fact. And time and resources are, naturally, tied to patient care, but they also affect the budget. That's a major difficulty for the clinic and for hospital management as well. Third, infections. Urinary infections acquired in hospitals rank as the leading cause of infection within hospitals. And what makes this critical here is that the patient has a catheter in place. There's a substantial danger that bacteria travel the wrong direction, from the collection system up to the patient. That produces infections and also the need to use antibiotics. This, naturally, is a liability, a cost, and a clinical issue all at once. So these are clearly meaningful challenges to tackle. And what is Sippi? This is Sippi. Sippi performs the job that a urine collection measurement system performs in every ICU. It gathers the urine, yet it's very different. What does it do? It includes a bag, a disposable unit, and the base unit. And the base unit will compute the urine volume on its own, with great precision, each hour. So you get accurate data. It's entirely automated and is even linked to the patient data management system.
Bjorn Larsson
executiveThat gives you reliable information along with time savings. Beyond that, there are 2 features designed to prevent infections. The first goes by the name SippSense. Essentially, it detects when biofilm — the precursors of bacteria — rises too high within the system, and that triggers an alert to change the bag. The second is SippCoat, a truly fantastic innovation. This is a silicon oil that mixes with urine as it travels down from the patients into the bag, and it actively works against bacteria migration, thereby preventing infections. So clearly, this is a very robust product meeting very meaningful needs. So, meeting needs, a fantastic product, and the market opportunity — at present, SippiSystem is being launched. As you recall from November, this is a huge market. And at the moment, under the new leadership, we are looking into and further articulating that market opportunity. But for the time being, we stay with the estimate from November: roughly 500,000 base units globally per year and a total market of approximately NOK 4 billion. And right now, we are launching it in Europe. Next year — and we have already begun — we're planning a U.S. launch. Following that, we take — we are approaching Asia and the rest of the world.
Bjorn Larsson
executiveThe second piece of a major opportunity involves using the SippBag as a standalone product, though with a key SippCoat anti-infection feature included. We're currently assessing the rollout order and strategy for that bag, drawing on what we've learned from the launch now underway. So we'll also lay out those plans as we speak in the first part of 2020. That represents an enormous opportunity — a massive quantity of disposable bags, in a market estimated at roughly NOK 20 billion. It's exciting, but you have to proceed step by step and execute well in each phase. So here's a commercial update on Sippi, followed by one on Observe Medical. Sippi BLE has gotten a great response, addressing needs that are truly relevant to the customer, and the response has been great. What we've learned concerns implementation. We have a huge opportunity, and the stressed ICU team requires a very robust implementation and approach from us. And over the last couple of months, we've learned about that. Now we're raising the activity level and increasing our training for the distributor, and we all recognize that's the right path forward. And speaking of the value proposition, to achieve that, we have plenty of evidence backing the value of Sippi. But that work is ongoing, and I'll return to it.
Bjorn Larsson
executiveI'm glad to share that we recently had a quite significant bacterial study carried out at Karolinska Hospital accepted as an abstract, and the complete paper is now under review. I'll be able to share a bit more with you very shortly. When it comes to engaging with the community, what we offer isn't just a product — it's a solution that tackles real problems, and we have to raise the bar in how we discuss Sippi and how we approach these matters. That's why we're deeply involved, particularly within the Nordic life science community, to ensure we're both understood and appreciated. For instance, we work with Norway HealthTech and Swedish Medtech organizations. To further strengthen clinical and health economics evidence along with engagement from opinion leaders, I'd like to mention Jan van der Linden. He is a professor at the Thoracic Clinic in Stockholm. He has been involved with developing Sippi and is curious about it, since he believes it could represent an important next step for clinical practice. So he has also been testing the Sippi system and has run a number of tests as well. One of those tests is the bacterial study I just mentioned. And at this point we can share some key facts about that study.
Bjorn Larsson
executiveIt confirmed that among all the infections patients in the ICU who are catheterized get, the source is the system itself. This is known as a retrograde urinary infectant. That matters. That is the weight of the problem. He can also see that in fact SippCoat only hindered and inhibited biofilm and bacteria formation even when antibiotic-resistant bacteria were present. And then he suggests these could be an important step toward better clinical practice for such patients. These results from this study, which by the way is a totally independent study, make us proud and humble. So we are confident, and we are humble about the challenge. And we believe it is a very meaningful journey that we are embarking on with Observe Medical and Sippi. With that, I would like to invite Per Arne Nygard to tell us about the financials.
Per Nygård
executiveThanks, Bjorn, and thanks for that introduction. I'll be walking you through the 2019 financials — covering both Q4 and the full year. This statement follows the same principle as the carve-out 2018 financial statement. So let's begin with a few key figures from the profit and loss. As Bjorn mentioned, the company is in a launch phase. That means even though revenue went up from 2018, it's still at a low level. Operating expenses rose both in the quarter and across the full year of 2019. Costs and expenses tied to the listing and the merger process come to roughly NOK 1.7 million. And naturally, in Q4 we also had expenses connected to establishing Observe Medical as a standalone publicly listed company. Net finance is linked to, or affected by, the change in the contingent consideration. That liability is described in Note 11 to the carve-out statements for 2018. And in 2018, there was a significant reduction in this liability, which had a positive effect on finance for both the full year and Q4. In 2019, those effects showed up in Q4, but for the full year, the liability went up somewhat. That produces a result of minus NOK 4.5 million for the quarter and NOK 16.9 million for the full year.
Per Nygård
executiveLet me share a few remarks on the balance sheet. Intangible assets are made up of Sippi — a patent — along with capitalized development costs. Starting January 1, the company also applied IFRS 16 for leases, which forms part of the tangible asset. You'll also note that IFRS 16 appears within both current and noncurrent liabilities. As some of you likely recall from the merger and listing, one element involved converting the NOK 60 million debt owed to Navamedic, which affected equity. So at year-end, equity stands at NOK 14.5 million, with net interest-bearing debt — or interest-bearing debt — of NOK 25.4 million. That interest-bearing debt also includes the accrued interest as of December. A few words now on the cash flow statement. Net cash from operating activities came in at minus NOK 14 million, made up of negative EBITDA of NOK 11.5 million, and we also saw a decrease in trade payables during the year. The company invests in our products. In 2019, investment in Sippi amounted to NOK 2.1 million. And as noted on the balance sheet, we have this debt conversion of NOK 16 million plus increased debt of NOK 200,000, giving a positive financing effect of NOK 16.2 million.
Per Nygård
executiveAt the close of the year, our cash balance stood at NOK 0.5 million. That wraps up the financial update. I'll now hand things back to Bjorn for the summary and outlook.
Bjorn Larsson
executiveThank you, Per Arne. Thank you. And summary and outlook. And I just wanted to repeat. We are standing here in the beginning of 2020. Look back to 2 intense or 3 intense months during the last part of the year, where Per Arne and I came on board mid-December, actually. And really good start. We got successful listing -- demerger and listing and we more or less instantly increased activities and started commercially shape our organization and team and establish ourselves. And Sippi is our key focus. And -- oh, sorry. And onwards, I would change execution, execution, of course, careful execution and planning, but execution. And we're going to keep on executing the Sippi sales. In the Nordic, the next step is that Jan van der Linden in his clinic, we will actually implement the Sippi in all beds starting from March. And in the Nordic and in Europe, we have increased the activity levels with our distributor in the important markets of Germany and Italy as a focus. And during this period, we have got 3 tenders in Europe, two in the largest region in Sweden and one actually in Italy. So a lot of good things happening, a lot of traction.
Bjorn Larsson
executiveAnd it isn't just about revenue—it's also about getting to know the customers, since there's more than a single customer type out there. You've got different geographies, and you've got different customer segments. And we need to get ready for the U.S. launch, as we talked about in November. That will be a partnering strategy. We aren't establishing our business there alone, and that requires careful thought when it comes to a regulatory pathway and how the commercial pathway can secure good standing and a good launch. And as ever, building evidence for value-based pricing, and we're eager to build further on the bacterial study and studies of that kind. And we've also managed to engage Jan van der Linden and others on an important scientific and commercial advisory board, which will support our commercial pathway going forward. And to wrap up on execution, we're always looking out for well-fitting market mergers and acquisition cases. You'll remember, we're a platform for growth through Sippi commercialization and through building a carefully crafted portfolio in Medtech. And on behalf of the Observe team, Per Arne and myself, thank you for your attention, and we'll now open things up for questions and answers in the room and from the webcast.
Bjorn Larsson
executiveDoes anyone in the room have a question? And are there any questions coming in from the web?
Executive
executiveThere aren't any questions.
Bjorn Larsson
executiveAll right. All right. That brings us to the end, then. We genuinely appreciate your interest — both those of you who joined us here today and those taking part. And I'd like to finish by saying a word about how much you matter to us. You're placing your trust in us on this journey, and your input is something we need. Your hard questions are needed too, and we need to be challenged as well as supported along the way, and going forward we're committed to being open, transparent and communicative with you in a very fair manner. So with that, thank you, and we'll see you again soon.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Observe Medical ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Observe Medical ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Observe Medical ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.